Search

Poster presentations: Clinical: Diagnosis and Outcome 2022

P108 Identifying Patient-Centered Future Research Priorities: A Report from the Patient Reported Outcomes after Pouch Surgery (PROPS) Delphi Consensus Study

P109 Risk of cervical cancer in incident Ulcerative Colitis during the first 10 years after diagnosis: A nationwide population-based study

P110 Risk Factors of Clinical Relapses in Pediatric Luminal Crohn’s Disease, a Retrospective Cohort Study

P111 Gut barrier markers in Inflammatory Bowel Disease

P112 The road to disease control: Combination of histologic and endoscopic remission predicts long-term disease outcome in ulcerative colitis

P113 Defining the Safety of Early Ileostomy Closure After IPAA

P114 SARS-CoV-2 infection in IBD: pandemic waves and predictors of severe or persistent COVID-19

P115 Implementation of a vaccination tool in the electronic patient health record significantly increases vaccination coverage

P116 Screening for low BMI and unintentional weight loss alone is insufficient to identify patients at risk for malnutrition in an outpatient IBD population

P117 point-of-care intestinal ultrasound for the detection of postoperative Crohn's disease endoscopic recurrence

P118 Inflammatory Bowel Disease Unclassified and Ulcerative Colitis: different outcomes? Multicenter case-control study (Spanish ENEIDA registry)

P119 Hereditary Colorectal Cancer Syndromes and Inflammatory Bowel Diseases: an ECCO CONFER Multicenter Case Series.

P120 First year remission rates among patients with newly diagnosed Crohn’s disease: data from a real-world prospective inception cohort

P121 Second-Line Biologic Therapy Persistence in a Multicentre Cohort of Inflammatory Bowel Disease Patients

P122 Low Risk of new dysplastic lesions during inflammatory bowel disease surveillance with dye-cromoendoscopy: a multicenter population-based retrospective study

P123 Characteristics of small bowel involvement and association with clinical outcome in patients with Crohn's disease

P124 Views of patients with Inflammatory Bowel Disease on their care during COVID-19 pandemic

P125 Ankylosing spondylitis can influence the outcome of inflammatory bowel disease

P126 The predictive value of the modified Rutgeerts score at index endoscopy after primary ileocolic resection in patients with Crohn’s disease for the risk of re-resection and severe endoscopic inflammation after long-term follow-up

P127 Type I collagen degradation fragments (C1M) and human neutrophil elastase-derived fragments of calprotectin (CPa9-HNE) reflect biochemical and endoscopic disease activity in patients with Inflammatory Bowel Disease

P128 Accuracy of the combination of transabdominal and transperineal ultrasound for the evaluation of Ulcerative Colitis activity

P129 Hepcidin and ferritin index can help to differentiate between different types of anaemia: an exploratory study

P130 Comparison of the clinical course of Ulcerative Colitis according to the presence or absence of clinical symptoms at the time of diagnosis

P131 Impact of Inflammatory Bowel Disease on patients’ caregivers: Results from a French cohort

P132 An audit of quality of histopathology reporting of colorectal mucosal biopsies for the diagnosis and assessment of Inflammatory Bowel Disease.

P133 Point-of-care measurement of infliximab and adalimumab trough levels by the fluorescence resonance energy transfer (FRET) assay

P134 Are hepatic steatosis predictive scores still useful to predict metabolic associated fatty liver disease (MAFLD) in Crohn’s disease patients?

P135 Usefulness of clinical and ultrasound indices to assess enthesis lesions in patients with inflammatory bowel diseases.

P136 Risk of polyps and colorectal cancer in patients with microscopic colitis: case-control study with long-term follow-up

P137 Lesions of Cytomegalovirus and Epstein Barr virus of the proximal gastrointestinal tract in patients with Inflammatory Bowel Disease after COVID-19.

P138 Psychometric validation and interpretation of a patient-reported outcomes instrument to assess bowel urgency among adults with moderate to severe Ulcerative Colitis

P139 Body composition and Crohn’s disease behavior: Is adiposity the main game changer?

P140 Immunomodulators are protective against severe COVID 19: results from a large multicentre cohort of inflammatory bowel disease patients

P141 Factors Associated with Time to Clinical Remission in Pediatric Luminal Crohn’s disease: a Retrospective Cohort Study

P142 Inflammatory bowel diseases associated with primary immunodeficiency: a multicenter study

P143 Changes in the Clinical Phenotype and Behavior of Pediatric Luminal Crohn’s Disease at Diagnosis in the Last Decade

P144 Changes of fecal metabolic and lipidomic features by anti-tumor necrosis factor treatment and prediction of clinical remission in patients with ulcerative colitis

P145 Ultrasonographic parameters associated with mucosal healing 1 year after infliximab therapy in Crohn’s Disease: a multicentric and prospective study

P146 Initial response to induction treatment more important than type of induction treatment for achieving sustained steroid free remission at 1 year in new-onset paediatric Crohn’s disease

P147 Do IBD Patient Treatment Outcomes Expectations Differ by Ethnicity and Gender?

P148 Subclinical inflammatory bowel disease precedes the diagnosis and leads to an increase on healthcare resources utilization: multicentric case-control study in the Basque Country

P149 Prioritising colonoscopy by faecal immunochemical test result does not delay the diagnosis of inflammatory bowel disease

P150 INCREASED RISK OF IBD FLARE AFTER SARS-CoV-2 INFECTION. WHO’S THE MORE GUILTY: VIRAL INFECTION OR THERAPY WITHDRAWAL?

P151 Rationalizing colonoscopy utilization for Inflammatory bowel disease diagnosis: time to reset the Calprotectin threshold to >600?

P152 Impact of disease location on burden of illness in patients with moderate-severe Crohn’s disease: A real-world survey in the United States, France, Germany, Italy, Spain, and United Kingdom (5EU)

P153 The impact of seton use on clinical and patient-reported outcomes in Crohn’s disease perianal fistulas: findings from a systematic literature review

P154 Evaluation of serum protein FingerPrint biomarkers of collagen, citrullinated vimentin and calprotectin in patients with inflammatory bowel disease

P155 Incidence and significance of vitamin D deficiency at Inflammatory Bowel Disease inception in the COVID era

P156 A multicentric study on the development and application of a deep learning algorithm for automatic detection of ulcers and erosions in the novel PillCam™ Crohn’s capsule

P157 Biologic therapy and short disease duration correlate with no dysplasia when colectomy performed for ulcerative colitis

P158 Disease and non-disease-related risk factors for inadequate bowel preparation in patients with inflammatory bowel disease: should the strategy be different?

P159 Faecal S100A12 as a non-invasive marker of inflammatory activity in Inflammatory Bowel Disease

P160 Pan-enteric mucosal inflammation in CD patients treated with vedolizumab – interim results of a prospective observational study using a panenteric capsule (PiilCam CD)

P161 Implementation of Outcome Measurement – Case Finnish IBD register

P162 Prevalence and incidence of nonalcoholic fatty liver disease in Inflammatory Bowel Disease patients: risk factors for progression

P163 Abdominal X-ray: an invaluable tool in Acute Severe Ulcerative Colitis

P164 Assessment of awareness and compliance with the recommendations of primary and secondary prevention of cancer in patients with Inflammatory Bowel Disease

P165 Characterization and risk of sarcopenia in patients with Ulcerative Colitis, compared with older and younger adults. Cross-sectional study.

P166 Predictive markers of Crohn’s disease in small bowel capsule endoscopy

P167 Functional outcomes of transanal versus transabdominal proctectomy with ileal pouch-anal anastomosis in Ulcerative Colitis. A comparative study.

P168 Matrix Gla protein, a potential marker of tissue remodelling and physiological ageing of the gut in Crohn’s Disease

P169 Delayed diagnosis of inflammatory bowel disease in women: Characterization and use of health resources

P170 Point-of-care ultrasound accurately quantifies skeletal muscle index in patients with Inflammatory Bowel Disease

P171 PSC/IBD and IBD have similar type and location of colonic lesions, but Dye ChromoEndoscopy (DCE) increases detection rate compared to White Light Endoscopy (WLE)

P172 Examining dysplasia surveillance in Inflammatory Bowel Disease and Primary Sclerosing Cholangitis - a real world experience.

P173 Endoscopic findings in the upper gastrointestinal tract in Crohn’s Disease – highly specific and closely related to Helicobacter pylori negative gastritis.

P174 Clostridium innocuum Infection in Inpatients with Inflammatory Bowel Disease

P175 Low relapse rates after biologic therapy discontinuation in a large real life cohort of IBD patients with initial severe disease: do biologics alter the natural history of disease?

P176 The effect of induction therapy with infliximab or vedolizumab on hepcidin and iron status in patients with Inflammatory Bowel Disease

P177 Validation of UC Intestinal Ultrasound (UC-IUS) Index for children with Ulcerative Colitis

P178 Fecal incontinence and rectal anal function in Crohn’s Diseases patients

P179 Distinct ultrasound characteristics of the appendix in patients with ulcerative colitis: a prospective, cross-sectional cohort study

P180 The prevalence and clinical course of atypical distribution of inflammation in newly diagnosed ulcerative colitis

P181 IBD patients with early clinical and sonographic improvements achieve better long-term outcomes than patients with clinical improvements alone – one-year interim results of the TRUST BEYOND study

P182 Twisted Pouch Syndrome: A Rare, Difficult to Diagnose Mechanical Complication of Ileal Pouch-Anal Anastomosis Amenable to Redo Pouch Salvage Surgery

P183 A systematic review on outcome measures of long-term efficacy in clinical trials concerning Crohn’s disease patients

P184 Relationship Between Patient Sex and Serum Tumor Necrosis Factor Antagonist Drug and Anti-Drug Antibody Concentrations in Inflammatory Bowel Disease; A Nationwide Cohort Study

P185 The role of neutrophil-lymphocyte ratio, neutrophil-monocyte ratio, and lymphocyte-monocyte ratio in estimating disease activity in patients with ulcerative colitis.

P186 Can transabdominal bowel ultrasound accurately detect both small and large bowel Crohn Disease in pediatric patients when compared to MRE?

P187 Major Depression in patients with Ulcerative Colitis and its relationship with clinical activity.

P188 Role of gastrointestinal ultrasound in severe Ulcerative Colitis: a real-life observational study from a tertiary center in Spain.

P189 Perceptions of Cannabis use in women with Inflammatory Bowel Disease of reproductive age: A cross-sectional study

P190 Implementation of IBD symptom diary – Case Finnish IBD register

P191 Development and validation of a 13-item short version of the IBD self-efficacy scale

P192 First event of acute intestinal inflammation and the risk of progression to Inflammatory bowel disease: a retrospective analysis

P193 Correlation of the IBD Disk scores with diagnosis of IBD, Faecal calprotectin and Endoscopic scores in patients presenting to a rapid access IBD inception clinic.

P194 A modified Rutgeerts score of i2a after ileocolic resection for Crohn’s Disease: endoscopic recurrence or anastomotic healing?

P196 Pre-treatment antibodies to infliximab and adalimumab are common but are not associated with anti-TNF treatment failure

P197 Anogenital Crohn’s disease and granulomatosis: A systematic review of epidemiology, clinical manifestations, and treatment

P198 An inflammatory serum metabolomic signature predicts response to vedolizumab treatment in people with Crohn’s Disease

P199 Ileal pouch-anal anastomosis in women of childbearing age affected by ulcerative colitis: a single-centre study on the risk factors for infertility and outcomes of pregnancy over 17 years.

P200 The diagnostic yield of pan-enteric capsule endoscopy in inflammatory bowel disease: A systematic review and meta-analysis

P201 Crohn’s Disease of the terminal ileum associated with ileo-sigmoid fistula: risk factors for ileostomy formation and postoperative complications during the years of biologics

P202 Performance characteristics of serum FGF19 measurement compared with the Se-HCAT retention test in the diagnosis of bile acid diarrhoea in Crohn’s Disease

P203 The performance of the Rutgeerts’ score, SES-CD, and MM-SES-CD for prediction of post-operative clinical recurrence in Crohn’s disease

P204 Endotrophin (PRO-C6) is associated with MRE confirmed intestinal strictures and Protein FingerPrint biomarkers of collagen degradation is associated with ulcerations in paediatric Crohn’s disease patients – results from the ImageKids study

P205 Eliakim and CECDAIic scores are useful pan-intestinal tools for CD diagnosis and activity monitoring

P206 Comparison of dye-spraying chromoendoscopy and virtual chromoendoscopy for colonic dysplasia detection in longstanding Inflammatory Bowel Disease

P207 COVID-19: a prevalence rate two times lower than that of the general population in French patients with Inflammatory Bowel Disease treated with intravenous biologic agents

P208 Enthesopathies in patients with inflammatory bowel diseases.

P209 Disproportionate low albumin and high neutrophil-to-lymphocyte ratio in small bowel adenocarcinoma in long-term Crohn's disease patients

P210 Assessment of disease specific knowledge and quality of life among patients with Inflammatory Bowel Disease

P211 Vaccination against Sars-Cov-2 in IBD patients: experience from a single tertiary referral centre

P212 The DUBLIN Score is a Useful Tool for Predicting Disease Course in Patients with Ulcerative Colitis

P213 Risk factors associated with NAFLD and liver fibrosis in patients with Inflammatory Bowel Disease: a prospective cohort study

P214 Plasma fatty acid binding protein 2, interleukin-10 and lipopolysaccharides as biomarkers for microscopic colitis

P215 Correlation between small bowel capsule endoscopy and biomarkers in postoperative recurrence in Crohn’s Disease

P216 Effect of the Crohn’s disease exclusion diet (CDED) on the fecal calprotectin level in children with active Crohn’s disease.

P217 Prevalence of COVID-19 in IBD patients treated with infliximab and vedolizumab in Croatian tertiary center – clinical observation of a case series

P218 Accuracy of Ultrasonography in Assessing Disease Activity in Pediatric Ulcerative Colitis: Preliminary Results of a two-center study

P219 Impact of COVID-19 pandemic in patients with a first consultation for suspected inflammatory bowel disease.

P220 CROHN'S DISEASE (CD): The predictive value of Montreal clinical patterns, and biological treatment in a Latin American IBD reference center.

P221 Association between Irritable Bowel Syndrome-type symptoms and Ulcerative Colitis: is it real?

P222 Raman Spectroscopy in the diagnosis of pIBD: experimental study

P223 Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in patient with intestinal Behçet’s disease as a marker of disease activity and prognosis

P224 Deconstructing distress: Stakeholder engagement for evidence-based, patient-centered interventions for the management of IBD-associated psychological distress

P225 David against Goliath: direct comparison of hand-held bowel sonography and magnetic resonance enterography for diagnosis of Crohn's disease

P226 Nuclear magnetic resonance spectroscopy measure of protein glycosylation is a biomarker of activity and metabolic complications in Inflammatory Bowel Disease.

P227 High prevalence of mental health illness in IBD patients with high caregiver burden in the developing world: An analysis of risk factors from the IBD Emerging Nations Consortium (IBD-ENC)

P228 Appendiceal Orifice Inflammation Is Associated with Lower Rate of Complete Endoscopic Remission in Patients with Ulcerative Colitis

P229 Capsule endoscopy is useful in the diagnosis and monitoring of postoperative recurrence in Crohn’s disease. Analysis from an 11-year cohort.

P230 Ultrasonography-based and Magnetic Resonance-based Lémann Index: two sides of the same coin

P231 Emergency Colectomy for IBD Is Not Associated with Increased Risk of Postoperative Infection, Reoperation or Readmission

P232 Depression and fatigue in active IBD from a microbiome perspective - a bayesian approach to faecal metagenomics

P233 Efficacy and safety of oral sulfate tablet for the bowel preparation in patients with inflammatory bowel disease: multicenter randomized controlled study

P234 Remission state in Inflammatory Bowel Disease patients on anti TNF or vedolizumab: a confocal endomicroscopy study

P235 The natural history of COVID-19 in vaccinated Inflammatory Bowel Disease patients

P236 Interobserver reliability of the Nancy index for ulcerative colitis: An assessment of the practicability and ease of use in a single-centre real-world setting.

P237 Proteomic analyses do not reveal subclinical inflammation in fatigued patients with quiescent Inflammatory Bowel Disease

P238 Symptom burden and indolent disease in newly diagnosed patients with ulcerative colitis and Crohn’s disease - a Copenhagen IBD Inception Cohort Study

P239 Ulcerative Colitis Index of Severity is a better predictor of histologic activity than Mayo endoscopic subscore, an Asian cohort study in ulcerative colitis.

P240 Influence of Covid-19 infection in patients with inflamatory bowel disease with biological and no biological therapy

P241 Advantages of a fully automated chemiluminescent method for therapeutic drug monitoring (TDM) of anti-TNFα in patients with Inflammatory Bowel Diseases

P242 Latent Tuberculosis: frequency of occurrence and effect on clinical, laboratory, endoscopic and morphological activity of the course Inflammatory Bowel Diseases

P243 Relationship between intestinal ultrasound, fecal calprotectin and Harvey-Bradshaw Index in the assessment of infllamatory activity in Cronh´s Disease

P244 COVID-19 vaccine does not increase the likelihood of disease exacerbation in IBD: results from a population-based study

P245 Dynemics of the Immune-transcriptome and Microbiome in Paediatric Inflammatory Bowel Disease

P246 Persistent burden of disease in patients with Crohn’s disease treated with biologic therapy: results from a real-world survey in the United States (US), France, Germany, Italy, Spain, and United Kingdom (5EU)

P247 Comparison of discontinuation/switching between infliximab biosimilar and originator among Inflammatory Bowel Disease patients: a real-world analysis of two Canadian cohorts

P248 Lifestyle changes after Inflamatory Bowel Disease diagnosis.

P249 Serum calprotectin is useful to confirm Inflammatory Bowel Disease activity but is not effective to predict relapse.

P250 Clinical validation of a point of care test for fecal calprotectin in distinguishing irritable bowel syndrome from Inflammatory Bowel Disease

P251 Endoscopic and pathologic findings of the esophago-gastroduodenal involvement of Crohn’s disease in Korea: a prospective cohort study

P252 Low adherence is associated with worse disease course in Ulcerative Colitis: a retrospective study from a single referral center.

P253 Are we doing enough to prevent colectomy in Inflammatory Bowel Disease (IBD) patients? A 5-year review of colectomy rates in Shropshire and Mid-Wales UK (2015-2019).

P254 Crohn’s disease of the pouch: an overdiagnosed condition?

P255 Mirikizumab modulates genes associated with the symptom of bowel urgency

P256 The practical use of an eHealth platform for inflammatory bowel disease patients: the validation of the IBD Tool web-based tele-monitoring system

P257 The clinical decision support tool has low performance in predicting outcome to ustekinumab in Crohn’s disease

P258 Impact of inflammatory bowel diseases on the phenotype and severity of primary sclerosing cholangitis - a systematic review with meta-analysis

P259 Metabolic associated Liver Disease and sex as key factors of cardiovascular risk in Inflammatory Bowel Disease

P260 Autoimmune pancreatitis in patients with Inflammatory Bowel Disease: results from a multicentre ECCO CONFER cases series

P261 Burden of bowel urgency across specific treatment groups among Ulcerative Colitis patients – real world global study analyses

P262 Decreased infliximab trough levels (TLI) is a moderate predictor of loss of response to IFX in IBD patients.

P263 Very early onset Inflammatory Bowel Diseases: Review of the Genoa-Messina joint clinical experience. Clinical history: Part I.

P264 Prevalence and predictors of stoma formation and restoration of intestinal continuity in patients with Crohn’s disease in a tertiary referral hospital: A retrospective explorative study

P265 Open approach for ileocolic resection in Crohn’s disease in the era of minimally invasive surgery: indications and perioperative outcomes in a referral centre.

P266 Elderly-onset Inflammatory Bowel Disease: a retrospective single-center study with current follow-up

P267 Milan Ultrasound Criteria are accurate in assessing endoscopic remission and treatment response in patients with ulcerative colitis

P268 IBD and Covid-19 in italy: comparisons between first and second pandemic wave

P269 Spaciotemporal machine learning analysis of complete small bowel capsule endoscopy videos for prediction of outcomes in Crohn's disease

P270 Ultrasonography interobserver agreement in Crohn Disease between experienced and non expert operators

P271 Fecal calprotectin at diagnosis is associated with oral steroid use first year of Inflammatory Bowel Disease.

P272 Psychological burden in newly diagnosed IBD patients: Differences between Crohn's Disease and Ulcerative Colitis in early IBD

P273 Inflammatory Bowel Disease and COVID-19 vaccine

P274 Bioelectrical impedance analysis identifies low skeletal muscle index in patients with Inflammatory Bowel Disease

P275 New non-invasive biomarkers of intestinal inflammation in pediatric inflammatory bowel diseases and their correlation with fecal calprotectin – pilot study.

P276 Prevalence, clinicopathological, and biological characteristics of serrated polyps in　patients with ulcerative colitis

P277 Assessment of fatigue as a patient-reported outcome: Correlation with baseline disease activity and therapy response in Inflammatory Bowel Disease

P278 Pan-enteric capsule to assess treatment effects of vedolizumab in IBD patients: A 1 year proof of concept study

P279 Prevalence of iron deficiency in inflammatory bowel disease

P280 Prognosis of patients with Crohns Disease in transmural remission with gastrointestinal ultrasound

P281 TELEIBD: A telematic fast-track pathway for patients with high suspicion of Inflammatory Bowel Disease in primary care.

P282 Influence of phenotype at diagnosis and of other potential prognostic factors on the prognosis of Crohn’s Disease in Chinese population